Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 4/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303662 | 0.86 | KDM4E (0.70) | MTNR1AMTNR1BHTR2AHTR1DMAPT | |
| SCHEMBL27788551 | 0.83 | HTR2C (0.75) | HTR2AHTR1DMAPTMPOSLC6A4 | |
| SCHEMBL31543697 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTSMN1; SMN2POLB | |
| SCHEMBL1771902 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTSMN1; SMN2POLB | |
| SCHEMBL2831695 | 0.82 | HTR2A (0.71) | MTNR1AMTNR1BHTR2AHTR1DMAPT | |
| SCHEMBL26664111 | 0.82 | MTNR1A (0.63) | MTNR1AMTNR1BHTR2AHTR1DMAPT | |
| SCHEMBL10310452 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BHTR2AHTR1DMAPT | |
| SCHEMBL6028824 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BHTR2AHTR1DMAPT | |
| SCHEMBL765005 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1BHTR2AHTR1DMPO | |
| Iodide SCHEMBL30672198 | 0.81 | MTNR1A (0.61) | MTNR1AMTNR1BHTR2AHTR1DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2011-06-30 | — | — | US | disclosed |
| CN-102018715-A | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | PHILADELPHIA HEALTH & EDUCATIO | 2011-04-20 | — | — | CN | disclosed |
| US-7767689-B2 | Carboline derivatives useful in the treatment of cancer | PTC THERAPEUTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100125065-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-05-20 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1534256-A4 | IMMUNOMODULATION AND EFFECT ON CELL PROCESSES RELATING TO SEROTONIN FAMILY RECEPTORS AND THE BLOOD-BRAIN BARRIER | PHILADELPHIA HEALTH & EDUCATIO (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060183757-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | Philadelphia Health and | 2006-08-17 | — | — | US | disclosed |
| US-20060135415-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | JAMESON BRADFORD A | 2006-06-22 | — | — | US | disclosed |
| US-20060039903-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors | JAMESON BRADFORD A | 2006-02-23 | — | — | US | disclosed |
| US-6979447-B2 | Immunomodulation and effect on cell processes relating to serotonin family receptors | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| CN-1674879-A | Immunomodulation and effects on cellular processes involving serotonin family receptors and the blood brain barrier | PHILADELPHIA HEALTH & EDUCATIO (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1534256-A2 | IMMUNOMODULATION AND EFFECT ON CELL PROCESSES RELATING TO SEROTONIN FAMILY RECEPTORS AND THE BLOOD-BRAIN BARRIER | Philadelphia Health and Education Corporation (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2003106660-A2 | IMMUNOMODULATION AND EFFECT ON CELL PROCESSES RELATING TO SEROTONIN FAMILY RECEPTORS AND THE BLOOD-BRAIN BARRIER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030100570-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (D/B/A MCH HAHNEMANN UNIVERSITY) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | MTNR1A 781/4885MTNR1B 644/4885HTR2A 2224/4885 |
| US-20060039903-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors | HTR6, HTR3B, HTR4 | MTNR1A 140/4885MTNR1B 37/4885HTR2A 10/4885 |
| US-20060135415-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | HTR2A, HTR1B, HTR5A | MTNR1A 189/4885MTNR1B 47/4885HTR2A 1/4885 |
| US-20060183757-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier | HTR2A, HTR1B, HTR5A | MTNR1A 189/4885MTNR1B 47/4885HTR2A 1/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | MTNR1A 398/4885MTNR1B 477/4885HTR2A 1527/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | MTNR1A 611/4885MTNR1B 644/4885HTR2A 1837/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | MTNR1A 781/4885MTNR1B 644/4885HTR2A 2224/4885 |
| US-20030100570-A1 | Immunomodulation and effect on cell processes relating to serotonin family receptors | HTR6, HTR3B, HTR4 | MTNR1A 140/4885MTNR1B 37/4885HTR2A 10/4885 |
| US-20100125065-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, KDR | MTNR1A 236/4885MTNR1B 129/4885HTR2A 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.